Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Presentation by Precision’s Marlon Graf Named an ISPOR 2023 Research Presentation Award Finalist
The presentation by Precision's Marlon Graf of a study with Jim Baumgardner, Iris Brewer, Jacquelyn Chou and Oliver Diaz and their colleagues was named an ISPOR 2023 Research Presentation Award Finalist. The Generalized Risk-Adjusted Cost-Effectiveness framework is a generalization of conventional cost-effectiveness analysis (CEA) and incorporates the effects of diminishing returns to health improvements as severity of illness increases. In the study presented by Marlon, the GRACE framework was applied to assess the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) compared to peginterferon alfa and ribavirin (PEG/riba), accounting for differential valuations of life years versus quality of life, disease severity, insurance value, and other novel value elements. Please reach out to Marlon to learn more about the GRACE framework.
Presentation by Precision’s Daniel Maciel Named an ISPOR 2023 Research Presentation Award Finalist
The presentation by Precision's Dylan Maciel of a study with Shannon Cope, Kevin Towle and Jeroen Jansen and their colleagues was named an ISPOR 2023 Research Presentation Award Finalist. Multi-level network meta-regression (ML-NMR) is a new method to perform network meta-analysis where for a subset of the studies we have individual participant data and for the remaining studies only aggregate level data from publications. In the study presented by Dylan, the feasibility of implementing ML-NMR for survival outcomes was evaluated. We learned a lot from this study that has direct benefit to future PRECISIONheor studies. Please contact Shannon Cope to learn more about ML-NMR (which is a method that is generalization of early work published by our Chief Scientist, Jeroen Jansen, in 2012).
Presentation by Precision’s Laura Panattonian at ISPOR 2023 Named the Best General Podium Research Presentation
The presentation by Precision's Laura Panattoni of a study with Tom Flottemesch, Natalie Land and Patrick Sullivan and their colleagues at ISPOR 2023 was named the Best General Podium Research Presentation. With this study, Laura and her colleagues aimed to quantify preferences for first line treatment attributes and treatment profiles among physicians who treat patients with aUC in 5 European countries (France, Germany, Italy, Spain, and the UK) with a DCE. Overall survival was the dominant attribute driving physicians’ choice of first line therapy, indicating that future therapies for aUC will need to provide substantial survival benefit to influence prescribing preferences. Reach out to Laura to learn more about this study.
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Download Now: Precision May Events Calendar
The MayEvents Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Download Now: Precision April Events Calendar
The April Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer
Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MDM Policy and Practice. The paper, entitled: "Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method" outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers. The authors also suggest the need for more support in the workplace for these individuals, and a holistic approach to accounting for these impacts in treatment decision making.
Download Now: Precision August Events Calendar
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
Incorporating Disease Transmission Dynamics Into Value Assessment
With focus in the COVID-19 pandemic shifting to treatments and managing severe forms of the disease, it's important to understand how health economists capture these dynamics to estimate the value of antiviral treatments. Precision's Jacquelyn W. Chou, Marissa Baker-Wagner, Marlon Graf, Zachary Heim, and T. Joseph Mattingly II provide recommendations for aligning the actual practice of value assessment of antivirals with best practice guidelines
Three Essential Tactics for Successful Drug Commercialization
One of the top tradeoffs faced by clinical stage biotech and pharmaceutical firms in raising capital to fund their clinical trial programs is the question of when and how to build a commercialization strategy, including navigating the complex work of securing market access. Precision's Ross Maclean and co-author Liz Turner discuss three high-value tactics that should be conducted early to avoid costly missteps that could impact product success.
Seven Strategies for Succeeding as a Small Fish in a Big Pond
Emerging biotech organizations have had to become both resourceful and creative since the start of the COVID-19 pandemic. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace. The pressure on emerging and small biotech companies to do more with less and maximize results is only projected to continue. Precision's Ross Maclean and co-author Liz Turner identify seven key attributes that favor the smaller biotech.
Featured Expert: Walter Bouwmeester
This month, PRECISIONheor highlights Director, Walter Bouwmeester.
Demonstrating the short-term and long-term value of gene and cellular therapies
In this on-demand webinar, a panel of Precision's top gene and cell therapy leaders tackles the challenge of how to demonstrate the short and long-term value of a therapy when clinical data is lacking.
On-demand HEOR webinar: 4 trends for market access in 2020
This expert panel tackles head-on some of the hottest topics and trends in health economics and outcomes research today, and what you need to know to be successful in 2020.
Critical pitfalls to avoid in value-based contracting
Adapted from Steve's recent presentations at the AMCP and ISPOR conferences, this on-demand webinar will provide an overview of value-based contracting and some of the key challenges to successful implementation.
On-demand webinar with Dr. Anupam Jena: What do value assessments miss?
In this unique one-hour webinar, Dr. Jena outlines a framework for assessing value to improve high-value treatments and identify low-value therapies on which spending can safely be reduced.
Register for Precision HEOR’s free on-demand webinar: Improving evidence synthesis methods
Hear from globally recognized expert Dr. Jeroen Jansen on how to improve your evidence synthesis approaches to understand value, with applications to oncology.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. Precision's Jenny Chen, Sam Keeping and Julie Park joined other experts to conduct a large, retrospective chart review of European patients with R/R MCL with prior BTKi therapy (SCHOLAR-2).
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions
HEOR data can help to close knowledge gaps and uncertainties that payers may possess when making decisions involving access and reimbursement. Precision's Jacquelyn Chou, Alexandria Portelli and Andrew Cournoyer discuss important steps in prelaunch HEOR planning to support a successful market launch.
PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT
BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts
Congratulations to Precision's Iver Jensen for his contributions to "Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome," a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States.
Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome
Congratulations to Precision's Iver Jensen for his contributions to "Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome," a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States.